Telix Pharmaceuticals (TLX) investor relations material

Opening remarks and agenda

• AGM opened with confirmation of quorum, acknowledgment of traditional custodians, and addresses from the Interim Chairman and CEO outlining the agenda and formal business items.

• Meeting agenda included performance review, board introductions, strategic priorities for 2026, and procedural instructions for attendees.

Financial performance review

• Achieved $804 million in revenue for 2025, a 56% year-on-year increase, with Q1 2026 revenue at US $230 million, up 4% from the prior year.

• Q1 revenue increased by 11% quarter-on-quarter, with FY 2026 revenue guidance set at $950M–$970M.

• Illuccix and Gozellix expanded globally, now available in 22 countries, delivering over 2.9 million doses in 2025.

• Reinvestment of earnings prioritized for advancing new cancer treatments.

• Refinanced convertible bonds to extend financial flexibility and support growth.

Board and executive committee updates

• Three new U.S.-based directors appointed: David Gill, William Jellison, and Dr. Maria Rivas, strengthening expertise in healthcare, finance, and U.S. capital markets.

• Board renewal supports next phase of growth and dual ASX/Nasdaq listing.

• Board includes Interim Chair Mark Nelson, CEO Christian Behrenbruch, and several non-executive directors.

• David Gill to assume Chair role in the near future.